Ensemble Therapeutics Corp.
This article was originally published in Start Up
Executive Summary
Ensemble Therapeutics Corp. believes that its large-scale libraries of chemicals with macrocyclic structures will yield worthy drug candidates and ultimately marketable therapeutics. The hefty size of macrocyclic compounds is the key characteristic that Ensemble is banking on. Whereas small molecules generally interact with their targets by binding to them, Ensemble thinks macrocycles will be big enough to spread across the surface of disease-relevant proteins and so physically disrupt interactions that smaller molecules are too weak to influence. If so, macrocycles could hit targets that only protein therapeutics can address now, and potentially do so orally.
You may also be interested in...
Deals Of The Week: Isis Rethinks Its Partnering Strategy
Capitalizing on the interest that partners are showing in its beefed-up antisense pipeline, Isis has reset its partnering strategy to maximize the value of each asset. In other developments, Ensemble snagged Novartis in a discovery collaboration and Amgen returned glucokinase activator AMG 151 to Array.
Novartis Joins Ensemble To Develop An Oral IL-17 Blocker
Novartis is the latest big pharma to partner with Ensemble to develop oral small molecules against traditional biologic targets. Novartis will develop Ensemble’s synthetic macrocycle drug targeting IL-17, a pathway the big pharma knows well.
Boehringer Taps Ensemble Therapeutics In Deal For Macrocycle Drugs
In parallel with the Cambridge, Mass.-based company’s previous partnerships, Ensemble will discover synthetic macrocycle drugs that address protein-protein interactions, based on targets selected by the German pharma. Meanwhile, the biotech continues to develop its own pipeline.